The mission of St. Jude Children's Research Hospital is to find cures for children with catastrophic illnesses through research and treatment. The resources of the hospital have been focused on pediatric cancer throughout its 44 year history and the Cancer Center has been supported by a CCSG for 29 years. Through the support of the American Lebanese Syrian Associated Charities (ALSAC), a separate corporation whose only purpose is to raise money in support of St. Jude Children's Research Hospital, patients are accepted without regard to ability to pay. Public support of the hospital through ALSAC provides a strong foundation for our Cancer Center upon which extramurally funded research and CCSG support can be leveraged to their fullest potential. In the current application, six multidisciplinary research programs are described. The Molecular Oncology (MO) and Signal Transduction (ST) Programs focus on basic, discovery-oriented research. The Developmental Therapeutics for Solid Malignancies (DTSM), Hematologic Malignancies (HM), Neurobiology and Brain Tumor (NBT), and Cancer Prevention and Control (CPC) Programs emphasize the translation of laboratory or population science to clinical application. The latter program is new to this application and represents the culmination of a long-standing commitment to long-term follow-up of our patient population, a recent commitment to population sciences, and successful recruitment of a world-class scientist to lead efforts in this area. Research by the 139 members of the Cancer Center is supported by 12 Shared Resources and an outstanding clinical research infrastructure. During the previous funding period, a new Cancer Center Director was appointed and the overall structure of our Cancer Center and its leadership were enhanced by several organizational changes, including bringing the infrastructure supporting the expansive clinical trials efforts administratively under the Cancer Center's authority. Several Program leader changes and the successful recruitment of three new outstanding Department Chairs (Immunology, Chemical Biology, and Epidemiology/Cancer Control) during the last funding period significantly enhance the multidisciplinary science done by our Cancer Center Programs. St. Jude Cancer Center investigators had over 2000 cancer-related publications during the funding period, 20% of which represented intraprogrammatic interactions and 15% of which were inter-programmatic. Extramural support for cancer research done at St. Jude is currently over $50 million per year, $31 million of which is from the NCI/HHMI. St. Jude Children's Research Hospital recently went through a vigorous Strategic Planning process and made a strong and long-term commitment to remain focused on cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA021765-34S4
Application #
8637118
Study Section
Special Emphasis Panel (ZCA1-RTRB-Z (O1))
Program Officer
Marino, Michael A
Project Start
1997-04-01
Project End
2014-02-28
Budget Start
2013-03-01
Budget End
2014-02-28
Support Year
34
Fiscal Year
2013
Total Cost
$5,527,034
Indirect Cost
$2,368,729
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Nishii, Rina; Moriyama, Takaya; Janke, Laura J et al. (2018) Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy. Blood 131:2466-2474
Fernandez-Pineda, Israel; Davidoff, Andrew M; Lu, Lu et al. (2018) Impact of ovarian transposition before pelvic irradiation on ovarian function among long-term survivors of childhood Hodgkin lymphoma: A report from the St. Jude Lifetime Cohort Study. Pediatr Blood Cancer 65:e27232
Stewart, Elizabeth; McEvoy, Justina; Wang, Hong et al. (2018) Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses. Cancer Cell 34:411-426.e19
Broniscer, Alberto; Hwang, Scott N; Chamdine, Omar et al. (2018) Bithalamic gliomas may be molecularly distinct from their unilateral high-grade counterparts. Brain Pathol 28:112-120
Wogksch, Matthew D; Howell, Carrie R; Wilson, Carmen L et al. (2018) Physical fitness in survivors of childhood Hodgkin lymphoma: A report from the St. Jude Lifetime Cohort. Pediatr Blood Cancer :e27506
Halalsheh, Hadeel; Kaste, Sue C; Navid, Fariba et al. (2018) The role of routine imaging in pediatric cutaneous melanoma. Pediatr Blood Cancer 65:e27412
Wang, Lu; Hiler, Daniel; Xu, Beisi et al. (2018) Retinal Cell Type DNA Methylation and Histone Modifications Predict Reprogramming Efficiency and Retinogenesis in 3D Organoid Cultures. Cell Rep 22:2601-2614
Vanarotti, Murugendra; Evison, Benjamin J; Actis, Marcelo L et al. (2018) Small-molecules that bind to the ubiquitin-binding motif of REV1 inhibit REV1 interaction with K164-monoubiquitinated PCNA and suppress DNA damage tolerance. Bioorg Med Chem 26:2345-2353
Quinn, Melissa; Fannin, J T; Sciasci, Joseph et al. (2018) Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy. Antimicrob Agents Chemother 62:
Brinkman, Tara M; Recklitis, Christopher J; Michel, Gisela et al. (2018) Psychological Symptoms, Social Outcomes, Socioeconomic Attainment, and Health Behaviors Among Survivors of Childhood Cancer: Current State of the Literature. J Clin Oncol 36:2190-2197

Showing the most recent 10 out of 6764 publications